In a study of HER2 amplification and KRAS/BRAF mutation in stage II-III CRC patients, HER2 amplifications were less frequent in tumors with KRAS/BRAF mutations (observed in 0.2–1.4% of tumors harboring KRAS/BRAF mutations)1. Here, KRAS is linked to colorectal carcinoma.